Baseline Correlates of Complete Response to Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy in Patients with Relapsed and Refractory Multiple Myeloma: Subanalysis of the KarMMa Trial

被引：8
|
作者：
Shah, Nina [1 ]
Munshi, Nikhil C. [2 ]
Berdeja, Jesus G. [3 ,4 ]
Jagannath, Sundar [5 ]
Finney, Olivia [6 ]
Martin, Nathan [7 ]
Agarwal, Amit [7 ]
Rowe, Everton [7 ]
Campbe, Timothy B. [7 ]
San-Miguel, Jesus F. [8 ]
机构：
[1] UCSF, Med Ctr, San Francisco, CA USA
[2] Harvard Med Sch, Dana Farber Canc Inst, Boston, MA USA
[3] Tennessee Oncol, Nashville, TN USA
[4] Sarah Cannon Canc Ctr, Nashville, TN USA
[5] Mt Sinai Med Ctr, New York, NY USA
[6] Bluebird bio, Cambridge, MA USA
[7] Bristol Myers Squibb, Princeton, NJ USA
[8] Univ Navarra Clin, CIMA, CIBERONC, IDISNA, Pamplona, Spain
来源：
BLOOD | 2021年 / 138卷
关键词：
D O I：
10.1182/blood-2021-148375
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
1739
引用
收藏
页数：5
相关论文
共 50 条
  • [31] KarMMa-7, a Phase 1/2, Dose-Finding and Dose-Expansion Study of Combination Therapies with Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-Directed CAR T Cell Therapy for Relapsed/Refractory Multiple Myeloma (RRMM)
    Raje, Noopur S.
    Berdeja, Jesus G.
    Rodriguez-Otero, Paula
    Green, Damian J.
    Jagannath, Sundar
    Lonial, Sagar
    Gipson, Adrianna
    Caia, Andrea
    Martin, Nathan
    Yang, Zhihong
    Pittari, Gianfranco
    Mateos, Maria-Victoria
    BLOOD, 2021, 138
  • [32] Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma
    Anderson, Larry D., Jr.
    FUTURE ONCOLOGY, 2021, 18 (03) : 277 - 289
  • [33] Idecabtagene Vicleucel (ide-cel, bb2121) in Relapsed and Refractory Multiple Myeloma (RRMM): Analyses of high-risk patient (Pt) subgroups in the KarMMa study
    Goldschmidt, H.
    Raje, N. S.
    Siegel, D.
    Jagannath, S.
    Lonial, S.
    Munshi, N. C.
    Moreau, P.
    Cavo, M.
    Truppel-Hartmann, A.
    Rowe, E.
    Huang, L.
    Agarwal, A.
    Wang, J.
    Campbell, T. B.
    San-Miguel, J.
    Reece, D. E.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 18 - 19
  • [34] A Matching-Adjusted Indirect Comparison of Efficacy Outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a Bcma-Directed CAR T Cell Therapy Versus Conventional Care in Triple-Class-Exposed Relapsed and Refractory Multiple Myeloma
    Shah, Nina
    Ayers, Dieter
    Davies, Faith E.
    Cope, Shannon
    Mojebi, Ali
    Parikh, Kejal
    Dhanda, Devender
    Hari, Parameswaran
    Patel, Payal
    Huang, Liping
    Hege, Kristen
    Dhanasiri, Sujith
    BLOOD, 2020, 136
  • [35] Matching-adjusted indirect comparison of efficacy outcomes for Idecabtagene Vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, versus conventional care in triple-class-exposed relapsed and refractory multiple myeloma
    Goldschmidt, H.
    Shah, N.
    Ayers, D.
    Davies, F.
    Cope, S.
    Mojebi, A.
    Dhanda, D.
    Hari, P.
    Patel, P.
    Huang, L.
    Hege, K.
    Dhanasiri, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 205 - 206
  • [36] KarMMa study: Characterization of Cytokine Release Syndrome (CRS) in patients (Pts) with Relapsed and Refractory Multiple Myeloma (RRMM) treated with Idecabtagene Vicleucel (ide-cel, bb2121)
    Einsele, H.
    Kansagra, A.
    Lin, Y.
    Berdeja, J.
    Shah, N.
    Oriol, A.
    Yakoub-Agha, I
    Rambaldi, A.
    Truppel-Hartmann, A.
    Rowe, E.
    Wang, J.
    Agarwal, A.
    Campbell, T. B.
    Lonial, S.
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 : 208 - 209
  • [37] Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.
    Manier, Salomon
    Kansagra, Ankit J.
    Anderson, Larry D., Jr.
    Berdeja, Jesus G.
    Jagannath, Sundar
    Lin, Yi
    Lonial, Sagar
    Shah, Nina
    Raje, Noopur S.
    Siegel, David Samuel DiCapua
    Oriol, Albert
    Truppel-Hartmann, Anna
    Rowe, Everton
    Patel, Payal
    Agarwal, Amit
    Campbell, Timothy B.
    Rodriguez-Otero, Paula
    Munshi, Nikhil C.
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (15)
  • [38] ESTIMATION OF POST-INFUSION COSTS OF CARE FOR PATIENTS WITH RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM) WHO RECEIVED IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN THE KARMMA CLINICAL TRIAL
    Hari, P.
    Nguyen, A.
    Pelletier, C.
    Hege, K.
    McGarvey, N.
    Gitlin, M.
    Parikh, K.
    VALUE IN HEALTH, 2021, 24 : S29 - S30
  • [39] CHARACTERISTICS OF NEUROTOXICITY ASSOCIATED WITH IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN PATIENTS WITH MULTIPLE MYELOMA IN RECALLING AND REFRACTORY OF THE PIVOTAL STUDY PHASE 2 KARMMA
    Albert, Oriol
    Salomon, Manier
    Ankit, Kansagra
    Larry, Anderson Jr D.
    Jesus, Berdeja
    Sundar, Jagannath
    Yi, Lin
    Sagar, Lonial
    Nina, Shah
    Noopur, Raje
    David, Siegel
    Anna, Truppel-Hartmann
    Everton, Rowe
    Payal, Patel
    Amit, Agarwal
    Timothy, Campbell B.
    Paula, Rodriguez-Otero
    Nikhil, Munshi
    HAEMATOLOGICA, 2021, 106 (10) : 78 - 79
  • [40] EFFECTIVENESS AND SAFETY OF IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121) IN OLDER PATIENTS WITH MULTIPLE RECRACING / REFRACTORY MYELOMA (MMRR): SUBGROUP ANALYSIS OF THE KARMMA STUDY
    Paula, Rodriguez-Otero
    Jesus, Berdeja
    Noopur, Raje
    David, Siegel
    Yi, Lin
    Larry, Anderson D.
    Salomon, Manier
    Hermann, Einsele
    Michele, Cavo
    Anna, Truppel-Hartmann
    Everton, Rowe
    Jill, Sanford
    Julie, Wang
    Timothy, Campbell B.
    Sundar, Jagannath
    HAEMATOLOGICA, 2021, 106 (10) : 76 - 76
12345